Es Sclc News Today

Second-line treatment with sacituzumab govitecan-hziy led to responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.

The FDA has granted an orphan drug designation to alisertib (MLN8237) for the treatment of patients with extensive-stage small cell lung cancer.

Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.

Key opinion leaders share a focused discussion on lurbinectedin and its evolving role in small cell lung cancer following frontline therapy.

A brief review of the role that immunotherapy agents play in the frontline management of patients with small cell lung cancer.

Expert oncologists Laurent Greiller, MD, and Christian Grohé, MD, make introductions and review the current paradigm for small cell lung cancer diagnosis and classification.

A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.